BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9760608)

  • 1. A trial of dorzolamide for glaucoma.
    Gillies WE; Brooks AM
    Ophthalmic Surg Lasers; 1998 Sep; 29(9):728-32. PubMed ID: 9760608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of glaucoma with carbonic anhydrase inhibitors in eyewash: medium term retrospective experience with dorzolamide].
    Detry-Morel M; De Hoste F
    Bull Soc Belge Ophtalmol; 1997; 267():157-66. PubMed ID: 9745826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components.
    Strohmaier K; Snyder E; DuBiner H; Adamsons I
    Ophthalmology; 1999 Dec; 106(12 Suppl):1-9. PubMed ID: 10598691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience with COSOPT, the fixed combination of timolol and dorzolamide, gained in Swiss ophthalmologists' offices.
    Pajic B;
    Curr Med Res Opin; 2003; 19(2):95-101. PubMed ID: 12740152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial.
    Maruyama K; Shirato S
    J Glaucoma; 2006 Aug; 15(4):341-5. PubMed ID: 16865013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide.
    Clineschmidt CM; Williams RD; Snyder E; Adamsons IA
    Ophthalmology; 1999 Dec; 106(12 Suppl):17-24. PubMed ID: 10598693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience with Cosopt, the fixed combination of timolol and dorzolamide, after switch from free combination of timolol and dorzolamide, in Swiss ophthalmologists' offices.
    Gugleta K; Orgül S; Flammer J
    Curr Med Res Opin; 2003; 19(4):330-5. PubMed ID: 12841926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-year safety study of dorzolamide as monotherapy and with timolol and pilocarpine. Dorzolamide Safety Study Group.
    Adamsons IA; Polis A; Ostrov CS; Boyle JE
    J Glaucoma; 1998 Dec; 7(6):395-401. PubMed ID: 9871861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching from systemic to the topical carbonic anhydrase inhibitor dorzolamide: effect on the quality of life of glaucoma patients with drug-related side effects.
    Nesher R; Ticho U
    Isr Med Assoc J; 2003 Apr; 5(4):260-3. PubMed ID: 14509130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Manni G; Denis P; Chew P; Sharpe ED; Orengo-Nania S; Coote MA; Laganovska G; Volksone L; Zeyen T; Filatori I; James J; Aung T
    J Glaucoma; 2009; 18(4):293-300. PubMed ID: 19365194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of the European Glaucoma Prevention Study.
    Miglior S; Zeyen T; Pfeiffer N; Cunha-Vaz J; Torri V; Adamsons I;
    Ophthalmology; 2005 Mar; 112(3):366-75. PubMed ID: 15745761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effectiveness of dorzolamide as added therapy in glaucoma patients with maximum tolerated drug therapy. A pilot study].
    Denk PO; Knorr M; Kriegerowski M; Thiel HJ
    Klin Monbl Augenheilkd; 1997 Jun; 210(6):360-4. PubMed ID: 9333661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dorzolamide/timolol combination versus timolol plus pilocarpine: patient preference and impact on daily life. United States Patient Preference Study Group. International Patient Preference Study Group.
    Sverrisson T; Gross R; Pearson J; Rusk C; Adamsons I
    J Glaucoma; 1999 Oct; 8(5):315-24. PubMed ID: 10529932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost.
    Tamer C; Oksüz H
    Ophthalmic Res; 2007; 39(1):24-31. PubMed ID: 17164574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical versus oral carbonic anhydrase inhibitor therapy for pediatric glaucoma.
    Portellos M; Buckley EG; Freedman SF
    J AAPOS; 1998 Feb; 2(1):43-7. PubMed ID: 10532366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of dorzolamide 2% added to timolol maleate 0.5% on intraocular pressure, retrobulbar blood flow, and the progression of visual field damage in patients with primary open-angle glaucoma: a single-center, 4-year, open-label study.
    Martínez A; Sánchez M
    Clin Ther; 2008 Jun; 30(6):1120-34. PubMed ID: 18640468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of dorzolamide-timolol combination versus the concomitant drugs.
    Choudhri S; Wand M; Shields MB
    Am J Ophthalmol; 2000 Dec; 130(6):832-3. PubMed ID: 11124307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Trusopt--a new form of drug for treating glaucoma].
    Izdebska J
    Klin Oczna; 1997; 99(3):217-20. PubMed ID: 9456571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Timolol 0.5%/dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine 2% fixed combination in primary open-angle glaucoma or ocular hypertensive patients].
    Kałuzny JJ; Szaflik J; Czechowicz-Janicka K; Kałuzny J; Orzałkiewicz A; Zaleska-Zmijewska A; Krajewska M; Stewart JA; Leech JN; Stewart WC
    Klin Oczna; 2004; 106(1-2 Suppl):241-2. PubMed ID: 15510513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of 2% dorzolamide on retinal blood flow: a study on juvenile primary open-angle glaucoma patients already receiving 0.5% timolol.
    Costagliola C; Campa C; Parmeggiani F; Incorvaia C; Perri P; D'Angelo S; Lamberti G; Sebastiani A
    Br J Clin Pharmacol; 2007 Mar; 63(3):376-9. PubMed ID: 16981897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.